Results from HIVEC-II for Intermediate-risk Non-muscle-invasive Bladder Cancer: Is This a Dead End for Mitomycin C Hyperthermia?

Affiliations

¹ Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
² GRC 5 Predictive Onco-Uro, Department of Urology, Sorbonne University, AP-HP, Pitié Salpétrière Hospital, Paris, France.
³ Department of Urology, Alzira University Hospital, Valencia, Spain. Electronic address: mirmare@yahoo.es.

Editorial

Clara Cerrato et al. Eur Urol. 2023 Jun.

. 2023 Jun;83(6):505-507.

doi: 10.1016/j.eururo.2023.03.004. Epub 2023 Mar 24.

¹ Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
² GRC 5 Predictive Onco-Uro, Department of Urology, Sorbonne University, AP-HP, Pitié Salpétrière Hospital, Paris, France.
³ Department of Urology, Alzira University Hospital, Valencia, Spain. Electronic address: mirmare@yahoo.es.

No abstract available

Comment on

Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial.
Tan WS, Prendergast A, Ackerman C, Yogeswaran Y, Cresswell J, Mariappan P, Phull J, Hunter-Campbell P, Lazarowicz H, Mishra V, Rane A, Davies M, Warburton H, Cooke P, Mostafid H, Wilby D, Mills R, Issa R, Kelly JD. Tan WS, et al. Eur Urol. 2023 Jun;83(6):497-504. doi: 10.1016/j.eururo.2022.08.003. Epub 2022 Aug 20. Eur Urol. 2023. PMID: 35999119 Clinical Trial.